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Background: Chemotherapy plus 1-year trastuzumab is the standard adjuvant treatment of HER2-positive breast cancer. The
efficacy of less extended trastuzumab exposure is under investigation. The short-HER study was aimed to assess the non-
inferiority of 9weeks versus 1 year of adjuvant trastuzumab combined with chemotherapy.
Patients and methods: HER2-positive breast cancer patients with node-positive or, if node negative, with at least one risk
factor (pT>2 cm, G3, lympho-vascular invasion, Ki-67> 20%, age35 years, or hormone receptor negativity) were randomly
assigned to receive sequential anthracycline–taxane combinations plus 1-year trastuzumab (arm A, long) or plus 9 weeks
trastuzumab (arm B, short). This study was designed as a non-inferiority trial with disease-free survival (DFS) as primary end
point. A DFS hazard ratio (HR)<1.29 was chosen as the non-inferiority margin. Analyses according to the frequentist and
Bayesian approach were planned. Secondary end points included 2-year failure rate and cardiac safety.
Results: A total of 1254 patients from 82 centers were randomized (arm A, long: n¼ 627; arm B, short: n¼ 626). Five-year DFS is
88% in the long and 85% in the short arm. The HR is 1.13 (90% CI 0.89–1.42), with the upper limit of the CI crossing the non-
inferiority margin. According to the Bayesian analysis, the probability that the short arm is non-inferior to the long one is 80%.
The 5-year overall survival (OS) is 95.2% in the long and 95.0% in the short arm (HR 1.07, 90% CI 0.74–1.56). Cardiac events are
significantly lower in the short arm (risk-ratio 0.33, 95% CI 0.22–0.50, P< 0.0001).
Conclusions: This study failed to show the non-inferiority of a shorter trastuzumab administration. One-year trastuzumab
remains the standard. However, a 9-week administration decreases the risk of severe cardiac toxicity and can be an option for
patients with cardiac events during treatment and for those with a low risk of relapse.
VC The Author(s) 2018. Published by Oxford University Press on behalf of the European Society for Medical Oncology.
All rights reserved. For permissions, please email: journals.permissions@oup.com.
Annals of Oncology 29: 2328–2333, 2018
doi:10.1093/annonc/mdy414
Published online 13 September 2018
D
ow
nloaded from
 https://academ
ic.oup.com
/annonc/article-abstract/29/12/2328/5096775 by R
ete Ligure Infor_Biom
ed user on 23 July 2019
Trial Registration: EUDRACT number: 2007-004326-25; NCI ClinicalTrials.gov number: NCT00629278.
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Introduction
Adjuvant pivotal trials with 1 year trastuzumab have significantly
improved the prognosis of HER2-positive early breast cancer,
leading to the approval of 12month administration as standard
adjuvant treatment [1–4]. However, the selection of 1-year ad-
ministration in these trials was largely empirical. Moreover, the
patients entered into these pivotal trials had a higher risk of re-
lapse, including mainly patients with node positive disease. In
addition, a small Finnish study, where trastuzumab was adminis-
tered for 9weeks, produced a meaningful disease-free survival
(DFS) benefit, with a favourable cardiac safety profile [5]. On
these premises, the Short-HER study was designed to evaluate the
non-inferiority of 9 weeks versus 1 year trastuzumab adminis-
tered in combination with a standard anthracycline–taxane
chemotherapy.
Methods
Study design
The Short-HER is a randomized, multicentric, investigator-driven study,
supported by the Italian National Drug Agency (AIFA). The trial was
approved by local ethical Committees, and conducted in compliance
with the principles of Good Clinical Practice and the Declaration of
Helsinki. An independent data monitoring committee monitored the
trial.
Participants
Women aged 18–75 with surgically resected, HER2-positive breast can-
cer, suitable for adjuvant chemotherapy were eligible. Women had to
have node positivity, or in case of node negativity, at least one of the fol-
lowing features: pathological tumour size >2 cm, histological grade 3,
presence of lympho-vascular invasion, Ki-67> 20%, age 35 years, or
hormone receptor negativity (ER and PgR< 10%). Normal liver, renal
and marrow function was requested, as well as left ventricular ejection
fraction (LVEF) within the institutional normal range. Patients with stage
IIIB/IV disease were not eligible.
Procedures
Patients screening information, confirmation of eligibility and random-
ization was carried out through a Web-based system. A permuted-blocks
randomization procedure was used, with patients stratified according to
nodal status (0, 1–3, 4þ), hormone-receptor status and regional coordi-
nating centres.
Chemotherapy in arm A (long) consisted of AC (adriamycin 60mg/
sqm plus cyclophosphamide 600mg/sqm) or EC (epidoxorubicin 90mg/
sqm plus cyclophosphamide 600mg/sqm) administered every 3weeks
for four courses followed by paclitaxel 175mg/sqm or docetaxel 100mg/
sqm every 3weeks for four courses. Trastuzumab was administered every
3weeks for 18 doses, starting with the first taxane dose (8mg/kg loading
dose at first cycle, and 6mg/kg thereafter).
Chemotherapy in arm B (short) consisted of docetaxel 100mg/sqm
every 3weeks for three courses followed by FEC (5-fluorouracil 600mg/
smq, epidoxorubicin 60mg/sqm, cyclophosphamide 600mg/sqm)
administered every 3weeks for three courses. Trastuzumab was adminis-
tered weekly for 9 weeks, starting concomitantly with docetaxel (4mg/kg
loading dose at first week, and 2mg/kg thereafter) (supplemental Figure
S1, available at Annals of Oncology online). After protocol amendment,
patients aged65 years received docetaxel 80mg/sqm in both arms.
LVEF measurements were repeated in arm A at the end of AC or EC
chemotherapy, and in Arm B at the end of docetaxel-trastuzumab. In
both arms, LVEF evaluations were repeated at 6, 9, 12, 18months from
randomization, and yearly thereafter.
When indicated, radiation therapy and hormonal therapy according
to local standard were carried out at the end of chemotherapy. Follow-up
including clinical examination, complete blood chemistry, chest radio-
gram and liver ultrasound were carried out every 6months during the
first 5 years and yearly thereafter. Mammography was repeated every
12months.
The primary end point was DFS, calculated as the time between ran-
domization and any of the following events, whichever first: local, region-
al and distant recurrence; contralateral breast cancer, excluding in situ
carcinoma; other second invasive primary cancer; death before recur-
rence or second primary cancer. Overall survival (OS), calculated as the
interval between randomization and patient death or last follow-up, was
evaluated as second primary analysis outcome. The hazard ratio (HR)
was used as measure of association for both the end points. It was esti-
mated as the ratio between the hazard rate of events following short treat-
ment and the hazard rate of events following long treatment.
Secondary end points included failure rate at 2 years (cumulative inci-
dence of relapse, contralateral breast cancer, death for all causes, treat-
ment withdrawal due to toxicity) and cardiac safety. Cardiac events were
defined as decrease of LVEF >15 percentage points from basal values, or
LVEF decrease >10 percentage points with absolute value below 50%, or
symptomatic congestive heart failure, or other cardiac side-effects grade
2 or more according to NCI CTCAE version 3.
Statistical analyses
This study is designed to assess whether a shorter trastuzumab adminis-
tration is non-inferior to the long one in respect with DFS. An HR<1.29
was set as a non-inferiority margin. The sample size was estimated by set-
ting a¼ 0.05 (one tail) and the power to 0.80, which resulted in 372
events and 2332 patients. However, a slower than expected rate of enrol-
ment was observed, and, in order to comply to AIFA timelines, the sam-
ple size had to be reduced to 1252 patients. The data analysis was planned
at the occurrence of the 198th event with a power of 0.56. HRs and its
90% confidence intervals for DFS and OS were estimated according to
the Coxmodel. The Bayesian analysis was planned at the beginning of the
study [6]. However, no a priori cut-off was pre-determined to consider
the Bayesian analysis positive. For this analysis, a non-informative prior
distribution was used.
For the evaluation of the 2-year failure rate, the measure of association
used was the relative risk, which was estimated as the ratio between the
risk of developing one of the events, whichever first, in the short treat-
ment and the risk of the events in the long one.
Results
A total of 1254 patients from 82 centers were randomized to arm
A (Long ¼627) and to arm B (Short ¼627); one HER2 negative
patient erroneously randomized was excluded from treatment
and analysis (supplement Figure S2, available at Annals of
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Oncology online). The baseline characteristics were balanced be-
tween the two arms with amedian age of 55 years, 54% of patients
with node negative disease, and 68% with hormone receptor
positive tumours (Table 1).
At a median follow up of six years, 200 DFS events were
reported: 95 (15%) in the long and 105 (17%) in the short arm,
respectively. Five-year DFS was 88% in the long and 85% in the
short arm (Figure 1A). The estimated HR was 1.13 (90% CI 0.89–
1.42) in the univariate Cox model with the upper limit of the CI
crossing the non-inferiority margin set at 1.29. Sub-group DFS
analysis according to age, stage, nodal status and hormone recep-
tor status is represented in Figure 1C, and suggests that the short
treatment might be inferior in stage III disease or in patients with
4þ positive nodes, although these differences are not statistically
significant. This group of patients represents 16% of the entire
patient population. DFS events distribution per treatment arm is
reported in supplemental Table S1, available at Annals of
Oncology online.
According to the pre-planned Bayesian analysis, which is based
on the observed data, assuming a non-informative prior distribu-
tion, the posterior probability that the short arm is not inferior to
the long one is 80% (Figure 1D).
The 5-year OS is 95.2% in the long (38 deaths) and 95.0%
(40 deaths) in the short arm, HR 1.07 (90% CI 0.74–1.56)
(Figure 1B).
Twenty-seven patients (4.3%) in the short-arm, and 82
(13.1%) in the long-arm experienced grade 2 cardiac adverse
events (risk-ratio 0.33, 95% CI 0.22–0.50, P< 0.001) (Table 2).
Figure 2 describes the time to cardiac event according to treat-
ment arm, showing consistent results (HR ¼0.32, 95% CI 0.21–
0.50; P< 0.0001).
The distribution of non-cardiac events was similar in the two
arms (supplemental Table S2, available at Annals of Oncology on-
line). Trastuzumab permanent discontinuation was reported in
53 (8.5%) patients in long arm and 21 patients (3.4%) in the
short arm. The 2-year failure rate was 8.6% in the short and 9.4%
in the long arm (risk-ratio 0.92, 95%CI 0.64–1.30).
Discussion
Notwithstanding the impressive results presented at the ASCO
2005 Meeting, which set 1 year trastuzumab as adjuvant treat-
ment of HER2þ early breast cancer [2, 3], the question on treat-
ment duration was still open. The empirical 1 year duration was
not based on sound biological and/or pharmacological data and,
in fact, the HERA trial was also exploring 2-year duration, with
final results showing no benefit over 1 year [7].
At the same time, the FinHer trial had shown that 9 weeks tras-
tuzumab could produce a significant decrease in risk of relapse
Table 1. Baseline patients characteristics, overall and by arm
Characteristics Randomized Short Long Overall
No. (%) No. (%) No. (%)
626 627 1253
Age (at randomization)
<60 408 (65) 394 (63) 802 (64)
60 218 (35) 233 (37) 451 (36)
Median age (range) 55 (25-78) 55 (28-78) 55 (25-78)
Menopausal status
Premenopausal 221 (35) 227 (36) 448 (36)
Postmenopausal 403 (64) 399 (64) 802 (64)
Pathological stage
I 264 (42) 245 (39) 509 (41)
II 268 (43) 281 (45) 549 (44)
III 91 (15) 100 (16) 191 (15)
Positive Lymph node
0 332 (53) 340 (54) 672 (54)
1-3 194 (31) 189 (30) 383 (30)
4þ 100 (16) 98 (16) 198 (16)
Hormone-receptor status
Negative 199 (32) 201 (32.) 400 (32)
Positive 427 (68) 426 (68) 853 (68)
HER2þ status
FISHþ 103 (16.5) 96 (15.3) 199 (15.9)
IHC2þ/FISHþ 95 (15.2) 91 (14.5) 186 (14.8)
IHC3þ 427 (68.2) 440 (70.2) 867 (69.2)
Negative 1 (0.1) 0 1 (0.1)
FISH, ﬂuorescence in situ hybridization; IHC, immunohistochemistry.
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[5]. Moreover, differently from real world population, these trials
had recruited mostly patients with node positive disease and low
risk of cardiac events. To address these issues, a network of aca-
demic and public hospitals in Italy designed the ShortHER trial
funded by the Italian Drug Agency (AIFA). Based on the specific
requirements of AIFA, ShortHER was designed as a non-
inferiority trial comparing a long regimen versus a short one and
both treatments had to be already available. The anthracycline–
cyclophosphamide regimen followed by a taxane with concomi-
tant 1 year trastuzumab based on B31 and N9831 data was chosen
as the standard treatment while three courses of a taxane with 9
weeks of concomitant trastuzumab followed by three courses of
FEC according to FinHER was the experimental arm. Therefore,
the ShortHER trial compares not only different trastuzumab
durations but also different chemotherapy regimens and the
planned cumulative doses of epidoxorubicin were 180 and
360mg/sqm in the short and long arm, respectively. The results
of the ShortHER trial do not allow to claim non-inferiority being
the HR 1.13 with the upper limit of CI crossing the pre-defined
boundary set at 1.29. Although underpowered, this study can
provide some important information. First of all, the characteris-
tics of the patients in the ShortHER trial are different in
comparison to those of the patients entered into the pivotal trials
with median age 55 years versus <50 years, and 54% node nega-
tive disease versus 0%–32%, respectively. These characteristics
are associated with a higher risk of cardiac events and lower risk
of disease relapse. In fact, although the definition of cardiac
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Figure 1. Study outcomes. (A) Kaplan–Meier plot of disease-free survival; (B) Kaplan–Meier plot of overall survival; (C) forest plot of disease-
free survival; (D) posterior distribution of treatment effect on DFS, Bayesian analysis. Probability of short treatment to be non-inferior to long:
0.80. Prior distribution: not informative. The HRs were obtained by exponentiating the estimated logHRs. The x-axis uses the logarithmic
scale.
Table 2. Cardiac adverse events (AEs) of grade2
Cardiac events Short Long
(n5 626) (n5627)
No. of patients with cardiac events (%)
Total 27 (4.3) 82 (13.1)
Grade max
2 19 (3.0) 64 (10.2)
3 5 (0.8) 15 (2.4)
4 3 (0.5) 3 (0.5)
Age
<60 17 (2.7) 52 (8.3)
60 10 (1.6) 30 (4.8)
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toxicity differs across trials, the incidence of cardiac events in the
pivotal trials was lower (ranging from 1.6 to 4.4 in N9831, B31
and HERA trials) than that observed in ShortHER. Our data,
however, are more in line with those reported from large popula-
tion studies of patients treated with adjuvant trastuzumab [8–10]
and show that a short treatment is associated with a significantly
lower cardiac toxicity. As far as risk of relapse is concerned, no
outcome difference in treatment arms has been observed in
patients with 0–3 positive nodes (85% of our patient popula-
tion) while 1-year trastuzumab seems to be associated with a bet-
ter outcome, although not significant, in stage III or 4þ positive
nodes patients.
Finally, according to the pre-planned Bayesian analysis, the
probability that a short treatment is not inferior to the long one is
80%, supporting that the hypothesis of non-inferiority cannot be
ruled out.
The issue of treatment de-escalation is an increasingly relevant
topic due to the availability of more effective treatments and
more favourable patient outcomes.
Some trials have addressed the de-escalation of chemotherapy.
BCIRG006 compared AC-docetaxel (AC-T) versus AC-
docetaxel þ trastuzumab (AC-TH) versus docetaxel–
carboplatin þ trastuzumab (TCbH) and, while confirming the
superiority of trastuzumab, proved that the non-anthracycline
TCbH regimen had a better cardiac tolerability (despite a 3%
DFS difference favouring the AC-TH arm) [4].
Two single arm phase II trials evaluated 12weeks of paclitaxel
(APT trial) or four courses of docetaxel/cyclophosphamide
(TCH trial) [11–13]. These trials mainly included patients at very
low risk, showed an extremely low relapse rate and these regimens
have been adopted and recommended in clinical practice for low-
risk patients.
De-escalated trastuzumab duration was addressed by the
Phare, SOLD and PERSEPHONE trials.
In the Phare trial, 3384 patients were randomised to receive
trastuzumab for 1 year versus 6 months; trastuzumab was given
either sequentially or concomitantly with chemotherapy. The
trial could not demonstrate the non-inferiority of 6 months tras-
tuzumab in the overall patient population [14]. However, a sub-
group analysis showed that a prognostic score based on nodal
status and T size, could identify a low-risk group of patients, rep-
resenting about one-third of the study population, with such a
good prognosis that the clinical value of 1 year trastuzumab could
be questionable [15].
In the SOLD trial, 2100 patients were randomised to receive
trastuzumab for 1 year or for 9weeks [16]. Differently from our
trial, the chemotherapy regimen was identical in the two treat-
ment arms. Again, non-inferiority could not be claimed being the
5 year DFS estimates 90.5% in long versus 88.0% in short arm. Of
interest, however, the 5 year distant DFS was very similar (94.2%
in long and 93.2% in short) while the cardiac toxicity was signifi-
cantly higher in case of 1 year trastuzumab (36 versus 21 cases of
congestive heart failure).
The PERSEPHONE trial randomised 4089 HER2þ patients to
receive trastuzumab for 6months or 1 year. At a median follow-
up of 4.9 years, the 4 years DFS was 89% in both arm with an HR
of 1.05 (confidence intervals included in the definition of non-
inferiority). Treatment interruptions due to cardiac events were
4% in the 6months arm and 8% in the 1 year arm (P< 0.0001)
[17].
Phare, SOLD and ShortHER, can be considered non-
conclusive, not having proved non-inferiority, while the larger
PERSEPHONE study has proved the non-inferiority of 6months
trastuzumab. Noteworthy, all the four trials have consistently
shown that a significant proportion of patients is at low risk of re-
lapse and a shorter trastuzumab treatment administration would
not compromise the outcome, while reducing the risk of cardiac
events. This information is clinically relevant as up to 8% of
patients in pivotal trials could not start trastuzumab and up to
15% had to discontinue trastuzumab because of cardiac events
[18–20].
In conclusion, the non-inferiority of 9 weeks trastuzumab can-
not be claimed on the basis of the frequentist approach. However,
a shorter trastuzumab administration could be an option for
those patients who experience cardiac events and for those with a
low risk of relapse. Moreover, this regimenmight facilitate the ac-
cess to trastuzumab to patients living in countries with limited
resources. Finally, a planned meta-analysis of individual patient
data from randomised trials, will allow to identify subgroups of
patients in which a shorter treatment can provide equivalent out-
comes with lower toxicity.
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